Drug Type Small molecule drug |
Synonyms Cobiprostone (USAN), RU-8811, SPI-8811 |
Target |
Mechanism CLCN2 agonists(Chloride channel protein 2 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC21H34F2O5 |
InChIKeySDDSJMXGJNWMJY-BRHAQHMBSA-N |
CAS Registry333963-42-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 2 | US | 01 Jun 2015 | |
Stomatitis | Phase 2 | US | 01 Jun 2015 | |
Hypertension, Portal | Phase 2 | US | 01 Jul 2008 | |
Osteoarthritis | Phase 2 | US | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | US | 01 Aug 2007 | |
Ulcer | Phase 2 | US | 01 Aug 2007 | |
Melanoma | Phase 2 | US | 01 Jun 2005 | |
Melanoma | Phase 2 | AU | 01 Jun 2005 | |
Gastroesophageal Reflux | Phase 2 | US | - | |
Nonalcoholic Steatohepatitis | Phase 2 | US | - |
Phase 2 | 121 | Placebo (Placebo) | eywxlctdto(vztozzimlq) = hznnkvtuia chvrxboegc (nnqwyxvmpo, lduybhpfzx - azyijmddxd) View more | - | 26 Dec 2019 | ||
Non-steroidal anti-inflammatory drug+Cobiprostone (Cobiprostone QD) | eywxlctdto(vztozzimlq) = tqeojnfmkm chvrxboegc (nnqwyxvmpo, odzghkjxed - vqviirgmyg) View more | ||||||
Phase 2 | 9 | (12 mcg TID) | etcxtfutox(nfzxclxoqo) = iuvbdtcbmo wtgifvriki (jhhmwowsxu, gendabvsyp - bqwdsmtpty) View more | - | 16 Mar 2016 | ||
(18 mcg TID) | etcxtfutox(nfzxclxoqo) = qlafcwgskw wtgifvriki (jhhmwowsxu, fquraslbxs - odvljkmxel) View more |